Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Senzime AB ( (SE:SEZI) ) just unveiled an announcement.
Senzime AB has announced the integration of its TetraGraph neuromuscular monitoring system with Mindray’s patient monitors, enhancing data connectivity and real-time patient data transfer. This integration strengthens Senzime’s competitive position by offering the broadest range of connectivity options in the industry, aligning with its strategy to make its technology a standard of care in hospitals worldwide.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph system, is used globally in operating rooms to ensure accurate neuromuscular monitoring during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 501,199
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.02B
See more insights into SEZI stock on TipRanks’ Stock Analysis page.